Dolutegravir/lamivudine

Drug Profile

Dolutegravir/lamivudine

Alternative Names: Lamivudine/dolutegravir

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 16 Mar 2017 ViiV Healthcare, in collaboration with GlaxoSmithKline, plans a phase I trial for HIV infections (In volunteers) (PO) (NCT03078556)
  • 01 Jun 2016 GlaxoSmithKline and ViiV Healthcare complete a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02738931)
  • 01 May 2016 Phase-I clinical trials in HIV infections (In volunteers) in USA (PO) (NCT02738931)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top